Zhejiang Conba Pharmaceutical Co (SHSE:600572) Piotroski F-Score: 8 (As of Jul. 27, 2026) — 33% Above Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:600572 Zhejiang Conba Pharmaceutical Co Ltd SHSE:600572
71 GF Score
Price ¥4.32
GF Value ¥5.51
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is Zhejiang Conba Pharmaceutical Co Piotroski F-Score?

Zhejiang Conba Pharmaceutical Co SHSE:600572 +2.61% 71 Piotroski F-Score is 8 as of Jul. 27, 2026, which is 33% above its 10-year median of 6.00. GuruFocus rates SHSE:600572 with a GF Score™ of 71/100 and a GF Value™ of ¥5.51 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 981 Drug Manufacturers companies, Zhejiang Conba Pharmaceutical Co ranks better than 98.27% on this metric.

Good Sign:

Piotroski F-Score is 8, indicates a very healthy situation.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Zhejiang Conba Pharmaceutical Co has an F-score of 8. It is a good or high score, which usually indicates a very healthy situation.

The historical rank and industry rank for Zhejiang Conba Pharmaceutical Co's Piotroski F-Score or its related term are showing as below:

SHSE:600572' s Piotroski F-Score Range Over the Past 10 Years
Min: 3   Med: 6   Max: 9
Current: 8

During the past 13 years, the highest Piotroski F-Score of Zhejiang Conba Pharmaceutical Co was 9. The lowest was 3. And the median was 6.

Zhejiang Conba Pharmaceutical Co  (SHSE:600572) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Zhejiang Conba Pharmaceutical Co Piotroski F-Score Related Terms


Zhejiang Conba Pharmaceutical Co Piotroski F-Score Historical Data

* Premium members only.

The historical data trend for Zhejiang Conba Pharmaceutical Co's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Zhejiang Conba Pharmaceutical Co Piotroski F-Score Chart

Zhejiang Conba Pharmaceutical Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.00 5.00 6.00 6.00 7.00

Zhejiang Conba Pharmaceutical Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.00 7.00 9.00 7.00 8.00

SHSE:600572 vs ZTS: Piotroski F-Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Zhejiang Conba Pharmaceutical Co's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Zhejiang Conba Pharmaceutical Co Piotroski F-Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Zhejiang Conba Pharmaceutical Co's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Zhejiang Conba Pharmaceutical Co's Piotroski F-Score falls into.


SHSE:600572
71GF Score
Zhejiang Conba Pharmaceutical Co Ltd SHSE:600572
Piotroski F-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Net Income was 164.212 + 230.427 + -109.672 + 198.45 = ¥483 Mil.
Cash Flow from Operations was 249.595 + 131.267 + 411.075 + 220.868 = ¥1,013 Mil.
Revenue was 1673.528 + 1617.233 + 1497.854 + 1905.513 = ¥6,694 Mil.
Gross Profit was 880.982 + 871.738 + 774.724 + 1081.234 = ¥3,609 Mil.
Average Total Assets from the begining of this year (Mar25)
to the end of this year (Mar26) was
(9969.002 + 9814.735 + 10133.26 + 9984.256 + 10219.553) / 5 = ¥10024.1612 Mil.
Total Assets at the begining of this year (Mar25) was ¥9,969 Mil.
Long-Term Debt & Capital Lease Obligation was ¥43 Mil.
Total Current Assets was ¥4,881 Mil.
Total Current Liabilities was ¥2,461 Mil.
Net Income was 166.136 + 136.259 + 103.959 + 189.396 = ¥596 Mil.

Revenue was 1624.207 + 1464.555 + 1602.156 + 1684.818 = ¥6,376 Mil.
Gross Profit was 851.45 + 748.637 + 822.363 + 923.385 = ¥3,346 Mil.
Average Total Assets from the begining of last year (Mar24)
to the end of last year (Mar25) was
(11310.399 + 10254.458 + 9749.198 + 9901.777 + 9969.002) / 5 = ¥10236.9668 Mil.
Total Assets at the begining of last year (Mar24) was ¥11,310 Mil.
Long-Term Debt & Capital Lease Obligation was ¥110 Mil.
Total Current Assets was ¥4,518 Mil.
Total Current Liabilities was ¥2,384 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Zhejiang Conba Pharmaceutical Co's current Net Income (TTM) was 483. ==> Positive ==> Score 1.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Zhejiang Conba Pharmaceutical Co's current Cash Flow from Operations (TTM) was 1,013. ==> Positive ==> Score 1.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Mar25)
=483.417/9969.002
=0.04849202

ROA (Last Year)=Net Income/Total Assets (Mar24)
=595.75/11310.399
=0.05267277

Zhejiang Conba Pharmaceutical Co's return on assets of this year was 0.04849202. Zhejiang Conba Pharmaceutical Co's return on assets of last year was 0.05267277. ==> Last year is higher ==> Score 0.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Zhejiang Conba Pharmaceutical Co's current Net Income (TTM) was 483. Zhejiang Conba Pharmaceutical Co's current Cash Flow from Operations (TTM) was 1,013. ==> 1,013 > 483 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Mar26)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar25 to Mar26
=43.433/10024.1612
=0.00433283

Gearing (Last Year: Mar25)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar24 to Mar25
=109.938/10236.9668
=0.01073931

Zhejiang Conba Pharmaceutical Co's gearing of this year was 0.00433283. Zhejiang Conba Pharmaceutical Co's gearing of last year was 0.01073931. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Mar26)=Total Current Assets/Total Current Liabilities
=4881.458/2461.237
=1.98333521

Current Ratio (Last Year: Mar25)=Total Current Assets/Total Current Liabilities
=4518.091/2384.315
=1.89492202

Zhejiang Conba Pharmaceutical Co's current ratio of this year was 1.98333521. Zhejiang Conba Pharmaceutical Co's current ratio of last year was 1.89492202. ==> This year's current ratio is higher. ==> Score 1.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Zhejiang Conba Pharmaceutical Co's number of shares in issue this year was 2544.229. Zhejiang Conba Pharmaceutical Co's number of shares in issue last year was 2959.31. ==> There is smaller number of shares in issue this year, or the same. ==> Score 1.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=3608.678/6694.128
=0.53908112

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=3345.835/6375.736
=0.52477628

Zhejiang Conba Pharmaceutical Co's gross margin of this year was 0.53908112. Zhejiang Conba Pharmaceutical Co's gross margin of last year was 0.52477628. ==> This year's gross margin is higher. ==> Score 1.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Mar25)
=6694.128/9969.002
=0.6714943

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Mar24)
=6375.736/11310.399
=0.56370567

Zhejiang Conba Pharmaceutical Co's asset turnover of this year was 0.6714943. Zhejiang Conba Pharmaceutical Co's asset turnover of last year was 0.56370567. ==> This year's asset turnover is higher. ==> Score 1.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=1+1+0+1+1+1+1+1+1
=8

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Zhejiang Conba Pharmaceutical Co has an F-score of 8. It is a good or high score, which usually indicates a very healthy situation.

Frequently Asked Questions Learn more about Piotroski F-Score →
What does a Piotroski F-Score of 8 mean?
Zhejiang Conba Pharmaceutical Co (SHSE:600572) has a Piotroski F-Score of 8 as of Jul. 27, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Zhejiang Conba Pharmaceutical Co and its competitors. This is 33% above median its historical median of 6.00. Over the past decade, Zhejiang Conba Pharmaceutical Co's Piotroski F-Score has ranged from 3.00 to 9.00. According to the industry distribution chart, Zhejiang Conba Pharmaceutical Co ranks #17 out of 981 companies in the Drug Manufacturers industry, placing it in the top 1.7%.
Is Zhejiang Conba Pharmaceutical Co's Piotroski F-Score too high?
Zhejiang Conba Pharmaceutical Co's current Piotroski F-Score of 8 is 33% above median its 10-year median of 6.00. Over the past 10 years, this metric has ranged from a low of 3.00 to a high of 9.00. The Drug Manufacturers industry median Piotroski F-Score is 5.00. Zhejiang Conba Pharmaceutical Co's value of 8 is 60% above this industry median. Based on the distribution chart, Zhejiang Conba Pharmaceutical Co ranks #17 out of 981 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Zhejiang Conba Pharmaceutical Co has a GF Score™ of 71/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Zhejiang Conba Pharmaceutical Co's Piotroski F-Score compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Zhejiang Conba Pharmaceutical Co ranks #17 out of 981 companies for Piotroski F-Score. This places Zhejiang Conba Pharmaceutical Co in the top 2% of its industry — outperforming the majority of peers. The industry median Piotroski F-Score is 5.00. Zhejiang Conba Pharmaceutical Co's value of 8 is 60% above this benchmark. Historically, Zhejiang Conba Pharmaceutical Co's own Piotroski F-Score has ranged from 3.00 to 9.00 over the past decade. While the company's 10-year median is 6.00 vs. the industry median of 5.00, Zhejiang Conba Pharmaceutical Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Drug Manufacturers company?
The median Piotroski F-Score among Drug Manufacturers companies is 5.00, based on 981 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Zhejiang Conba Pharmaceutical Co's current Piotroski F-Score of 8 is 60% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Zhejiang Conba Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median Piotroski F-Score is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Zhejiang Conba Pharmaceutical Co's current Piotroski F-Score is 8, which is 33% above median its own 10-year median of 6.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zhejiang Conba Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Zhejiang Conba Pharmaceutical Co (SHSE:600572) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥5.51, compared to a current price of ¥4.32 — trading 21.6% below its estimated fair value. The current Piotroski F-Score is 8, which is 33% above median its 10-year median of 6.00 and 60% above the Drug Manufacturers industry median of 5.00. Zhejiang Conba Pharmaceutical Co's overall GF Score™ is 71/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For Zhejiang Conba Pharmaceutical Co (SHSE:600572), the current Piotroski F-Score is 8 as of Jul. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Zhejiang Conba Pharmaceutical Co (SHSE:600572) Overvalued in 2026?

Based on GuruFocus' analysis, Zhejiang Conba Pharmaceutical Co stock appears to be undervalued. The current stock price of ¥4.32 is trading 21.6% below its estimated GF Value™ of ¥5.51. GuruFocus considers Zhejiang Conba Pharmaceutical Co to be Modestly Undervalued.

Key valuation signals for SHSE:600572:

  • Piotroski F-Score: 8 (33% above median its 10-year median of 6.00)
  • GF Value™: ¥5.51 vs. price of ¥4.32 (21.6% below fair value)
  • GF Score™: 71/100 with 4 warning signs
  • Industry Position: 60% above the Drug Manufacturers median (#17 of 981)

No single metric tells the full story. See the SHSE:600572 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Zhejiang Conba Pharmaceutical Co Business Description

Address No. 568 Binkang Road, New and High-Technology Development Zone, Binjiang District, Zhejiang, Hangzhou, CHN, 310052
Zhejiang Conba Pharmaceutical Co Ltd operates as a pharmaceutical company in China. It offers traditional Chinese medicines, botanical extracts, chemical medicines, chemical raw medicines, health foods, common foods, prepared drugs in pieces, and commodities. It provides its products under the Conba, Prostate Plus, Zhenshiming, Tianbaoning, Alocin, Xitao, Yuanbang, Baby, and Omeprazole names.
71GF Score

Get the complete analysis for SHSE:600572

Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥4.32
Price
¥5.51
GF Value